GSK Pharma’s shares surged 5% following the release of its Q4 FY25 financial results. The company’s consolidated revenue for the quarter increased by 4.8%, reaching Rs 974.4 crore compared to Rs 929.8 crore in the same period last year.
The company’s EBITDA saw a significant growth of 29.5%, rising to Rs 333.2 crore from Rs 257.3 crore in Q4 FY24. This resulted in a margin improvement to 34.2%, up from 27.7% in the previous year.
GSK Pharma’s net profit also experienced a strong jump, rising by 35% to Rs 262.9 crore from Rs 194.5 crore in Q4 FY24. The robust performance reflects a positive trend in the company’s operational efficiency and profitability.
The Board of Directors has proposed a final dividend of ₹42 per equity share on a face value of ₹10 each for the year ending March 31, 2025, subject to approval at the 100th Annual General Meeting. The record date for the dividend has been set for May 30, 2025.
GSK Pharma shares opened at 2,914.10, with a high of 3,025.00 and a low matching the opening value at 2,914.10. The stock’s 52-week high stands at 3,148.00, while the 52-week low is 1,921.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash